This Mind Medicine Australia webinar will cover:

• Overview of ketamine, including mechanism of action as a dissociative anesthetic and psychedelic medicine, history of its therapeutic use, and safety considerations (contraindications, inclusion/exclusion criteria)

• Overview of ketamine-assisted psychotherapy (KAP) as a promising treatment option for numerous difficult-to-treat mental health conditions

• Comparison of ketamine to other psychedelics and discussion around ketamine’s place in the field of mental health

• Real-world evidence supporting the use of ketamine and Spravato for patients with comorbid depression and anxiety, including safety and efficacy data, as well as cost-effectiveness and feasibility in an outpatient settings

• Other research assessing KAP, including a clinical pilot study for frontline health care workers and a group-based program for adults with eating disorders